The Potential Role of Long Noncoding RNAs in Primary Open-Angle Glaucoma

Feng Zhang  
Second Xiangya Hospital

Yang Zhao  
Second Xiangya Hospital

Mengdan Cao  
Second Xiangya Hospital

Xu Jia  
Guizhou Medical University

Zheng Pan  
Second Xiangya Hospital

Dengming Zhou  
Second Xiangya Hospital

Ke Liu  
Second Xiangya Hospital

Xuanchu Duan (✉ duanxchu@csu.edu.cn)  
Second Xiangya Hospital

---

Research article

Keywords: long noncoding RNA, primary open-angle glaucoma, trabecular meshwork

DOI: https://doi.org/10.21203/rs.2.19386/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background** To identify the potential genes in human trabecular meshwork (TM) related to primary open-angle glaucoma (POAG). At first, long noncoding RNA (LncRNA) and mRNA expression profiles in TM samples from 4 control subjects and POAG patients were accessed by microarray analyses. Then, twenty lncRNAs were validated by real-time quantitative PCR in the same samples from microarray analyses. Finally, eight highly expression lncRNAs were further tested by real-time quantitative PCR in TM from 8 normal controls and 19 POAG patients. Expression data were normalized and analyzed using the R software. Pathway analyses were performed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis.

**Results:** A total of 2179 lncRNAs and 923 mRNAs in the TM of POAG patients were significantly up-regulated, and 3111 lncRNAs and 887 mRNAs were significantly down-regulated. ENST00000552367, ENST00000582505, ENST00000609130, NR_029395, NR_038379, and ENST00000586949 expression levels were significantly higher in the TM from a different cohort of POAG patient than normal controls.

**Conclusion:** ENST00000552367, ENST00000582505, ENST000006091-30, NR_029395, NR_038379, and ENST00000586949 may play essential roles in the development of POAG.

**Background**

Glaucoma, after cataracts, is the most frequent cause of blindness worldwide\(^1\), affecting more than 60 million people. Also, the number of primary open-angle glaucoma (POAG) patients is estimated to be 45 million around the world\(^2\). Recognized risk factors for POAG include elevated intraocular pressure (IOP)\(^3\), genetic factors\(^4\), environmental circumstances\(^5,6\), refractive error\(^7\), and systemic diseases\(^8,9\).

With the discovery and study of noncoding RNAs which containing miRNAs, circular RNAs, and long noncoding RNAs (lncRNAs), the relationship between ncRNAs and diseases has raised concern in recently\(^10\). LncRNAs are defined as ncRNAs that are longer than 200 nucleotides, which play key roles in a variety of cellular processes through interaction with the main component proteins in gene regulatory systems\(^11\). Currently, lncRNAs were shown to take part in the biomarker\(^12\), development and progression of glaucoma\(^13\).

In our study, we sought to reveal disease-related lncRNA profiles in the trabecular meshwork of POAG patients. Our results showed that ENST00000552367, ENST00000582505, ENST000006091-30, NR_029395, NR_038379, and ENST00000586949 may plays an essential role in the development of POAG.

**Results**
Demographics and Characteristics of POAG cases and Controls

Our study included 23 human TMs from POAG patients and 12 healthy controls who donated their eyes after death from the Second Xiangya hospital, Central South University. The baseline characteristics of the subjects are summarized in Table 1. Subjects in the control and POAG groups were aged 49.83 ± 10.16 (mean ± SD) and 50.43 ± 9.72 years, respectively. The male percentage of the control and POAG groups were 58.33% and 43.48%, respectively.

Table 1
Clinical characteristics of subjects which trabecular meshwork was used in the study

| Characteristics   | Control (n = 12) | POAG (n = 23) |
|-------------------|-----------------|---------------|
| Age, mean ± SD, years | 49.83 ± 10.16   | 50.43 ± 9.72  |
| Sex, %            |                 |               |
| Male              | 58.33           | 43.48         |
| Female            | 41.67           | 56.52         |

Microarray expression profiling of lncRNAs and mRNAs in trabecular mesh from individual subjects

To detect and identify differentially expressed lncRNAs and mRNAs in the trabecular meshwork of POAG and normal patients, tissue samples were collected and quantified by microarray assays (Fig. 1). A total of 2179 lncRNAs and 923 mRNAs were significantly up-regulated (fold change ≥ 2, false discovery rate ≤ 0.05, P ≤ 0.05), and 3111 lncRNAs and 887 mRNAs were significantly down-regulated (fold change ≥ 2, false discovery rate ≤ 0.05, P ≤ 0.05), in POAG patients compared with control subjects.

GO and KEGG Pathway Enrichment Analysis

The Gene Ontology (GO) (http://www.geneontology.org) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis (http://www.genome.jp/kegg) were performed to explore potential functions of differentially expressed genes and correlated pathways. Dot plots (Fig. 2) showed the results of GO enrichment. The up-regulated mRNAs (Fig. 2A) include protein glycosylation, macromolecule glycosylation, glycosaminoglycan biosynthetic process, glycoprotein metabolic process, glycoprotein biosynthetic process, establishment of localization, establishment of blood-brain barrier, cellular response to zinc ion, carbohydrate derivative biosynthetic, and aminoglycan biosynthetic process. Whereas, biological process of down-regulated (Fig. 2B) mRNAs include vesicle targeting, synaptic transmission, glutamatergic, regulation of synaptic transmission, regulation of neurotransmitter levels, protein homo tetramerization, protein homo oligomerization, positive regulation of neurotransmitter, positive regulation of blinding, negative regulation of secretory, and golgi vesicle transport.
The KEGG pathway enrichment analyses showed that 10 pathways were significantly enriched in up-regulated genes (Fig. 3A), including ECM-receptor interaction, arrhythmogenic right ventricular cardiomyopathy (ARVC), glycosphingolipid biosynthesis-globo and isoglobo series, hypertrophic cardiomyopathy (HCM), malaria, glycosaminoglycan biosynthesis-heparan sulfate/heparin, vibrio cholerae infection, glycosaminoglycan biosynthesis-keratan sulfate, PI3K-Akt signaling pathway, and dilated cardiomyopathy. Moreover, ten pathways were enriched in down-regulated genes (Fig. 3B), including lysosome, tuberculosis, taurine and hypotaurine metabolism, amino sugar and nucleotide sugar metabolism, alanine, aspartate and glutamate metabolism, fatty acid degradation, arachidonic acid metabolism, fatty acid metabolism, long-term potentiation, amphetamine addiction.

**Real-time Quantitative PCR Validation**

To confirm the microarray analysis results and identify potential related lncRNA for development of POAG, 20 IncRNAs that had highly significant P values (P<0.01), large fold changes (>3.0) and false discovery rate (<0.025) and stated positive correlation with POAG-relevant mRNA were chosen and listed in Table 3. Their expression was assessed by individual RT-qPCR assays using the same samples from the initial microarray analysis (Fig. 4). Consistent with the microarray results, ENST00000422366, ENST00000430429, ENST00000514811, ENST00000552367, ENST00000582505, ENST00000609130, NR_029395, NR_038379, NR_110087, uc002rhy.1, ENST00000586949, and uc.3 + were significantly up-regulated (**P = 0.0002, *P = 0.0191, *P = 0.0431, ****P <0.0001, ***P = 0.0009, ****P <0.0001, ****P <0.0001, ****P <0.0001, ***P = 0.0009, **P = 0.0062, ****P = 0.0004, **P = 0.006, respectively) in the POAG group (Fig. 4). Otherwise, there were no significant differences in expression levels of ENST00000521373, ENST00000523317, ENST00000583377, ENST00000585387, NR_003039, NR_024249, NR_027425, and NR_046232 in trabecular meshwork samples between control and POAG groups (Fig. 4). As shown in Fig. 4, most genes (12/20) were consistent with the direction of changes acquired by microarray analysis, confirming the validity of the microarray data.
Table 3

A collection of IncRNAs detected using microarray in POAG patients

| Seqname       | Gene Symbol   | Type       | Source | Chrom | Fold Change | P-value   |
|---------------|---------------|------------|--------|-------|-------------|-----------|
| ENST00000422366 | HCG25         | noncoding  | GENCODE| chr6  | 6.2950477   | 0.000234483 |
| ENST00000430429 | AC098828.2    | noncoding  | GENCODE| chr2  | 8.012276    | 0.000732066 |
| ENST00000514811 | CTB-174D11.2  | noncoding  | GENCODE| chr5  | 3.0618575   | 0.000292896 |
| ENST00000521373 | CTB-43E15.2   | noncoding  | GENCODE| chr5  | 3.4622913   | 0.00000775870447 |
| ENST00000523317 | RP11-513H8.1  | noncoding  | GENCODE| chr8  | 9.2069013   | 0.00000010742317 |
| ENST00000552367 | RP11-290L1.3  | noncoding  | GENCODE| chr12 | 3.5869957   | 0.001808672 |
| ENST00000582505 | RP11-180P8.1  | noncoding  | GENCODE| chr17 | 4.5067869   | 0.007119343 |
| ENST00000583377 | RP11-848P1.5  | noncoding  | GENCODE| chr17 | 8.0630653   | 0.00000836198618 |
| ENST00000585387 | RP11-47L3.1   | noncoding  | GENCODE| chr17 | 3.5143649   | 0.0000277523881 |
| ENST00000609130 | RP11-1275H24.2| noncoding  | GENCODE| chr7  | 3.4213387   | 0.00077261 |
| NR_003039      | GLYCAM1       | noncoding  | RefSeq | chr12 | 3.4025491   | 0.0000478692165 |
| NR_024249      | FAM86C2P      | noncoding  | RefSeq | chr11 | 3.5783662   | 0.001026446 |
| NR_027425      | FAM66D        | noncoding  | RefSeq | chr8  | 5.0528304   | 0.00000084818513 |
| NR_029395      | IGLL3P        | noncoding  | RefSeq | chr22 | 3.3172646   | 0.00000083699526 |
| NR_038379      | LOC55420      | noncoding  | RefSeq | chr16 | 4.2303443   | 0.000650743 |
| NR_046232      | LINC01298     | noncoding  | RefSeq | chr8  | 3.7186282   | 0.000504244 |
| NR_110087      | LOC10192      | noncoding  | RefSeq | chr7  | 5.5122626   | 0.0000019212915 |
| Seqname    | Gene Symbol | Type            | Source         | Chrom | Fold Change | P-value         |
|------------|-------------|-----------------|----------------|-------|-------------|-----------------|
| uc002rhy.1 | AK125769    | noncoding       | UCSC_knowngene | chr2  | 6.7407795   | 0.0000196 368292 |
| ENST00000586949 | RP11-879F14.2 | noncoding       | GENCODE        | chr18 | 3.1115066   | 0.0001853 87    |
| uc.3+      | uc.3        | noncoding       | UCR            | chr1  | 5.1132223   | 0.0001377 04    |

To further confirm the results, more samples (8 cases of normal trabecular meshwork samples and 19 cases of POAG tissue samples) were collected and we confirmed that the expression of ENST00000552367, ENST00000582505, ENST00000609130, NR_029395, NR_038379, and ENST00000586949 were significantly up-regulated (**P = 0.0001, *P = 0.0113, ****P = 0.0001, **P = 0.001, ****P = 0.0001, ****P = 0.0001, respectively) (Fig. 5B, C, D, E, F, H). However, ENST00000422366 and NR_110087 shown no significant differences expression levels in trabecular meshwork samples between Control and POAG groups (Fig. 5A, G).

**Discussion**

Long non-coding RNA demonstrate ~ 10-fold lower abundance than mRNAs in a population of cells and characterized as tissue-specific\(^{14}\). In addition to higher tissue specificity, IncRNAs are characterized by higher developmental stage specificity\(^{15}\). Recent recognition that IncRNAs function in various aspects of cell biology has caused increasing attention on their potential contribution towards diseases etiology\(^{16}\). In the glaucoma research area, previous studies have indicated that there is a relationship between IncRNA and glaucoma. Lili Xie etc.\(^{12}\) identified IncRNAs T267384, ENST00000607393 and T342877 may be potential biomarkers for POAG diagnosis and ENST00000607393 might be a new therapeutic target for trabecular meshwork calcification based on clinical tissues. J. Zhao etc.\(^{11}\) concluded that IncRNA ANRIL attenuated oxidative injury of human TM cells and activated the mTOR and MEK/ERK pathways, possibly through down-regulation miR-7. Y. Xu etc.\(^{17}\) found that down-regulation of IncRNA GAS5 may maintain retinal ganglion cell survival in glaucoma through the activation of TGF-\(\beta\) pathway to promote cell proliferation and differentiation. Haibo Li etc.\(^{18}\) provided evidence that IncRNA-MALAT1 could inhibit RGC apoptosis in glaucoma through activation of the PI3K/Akt signaling pathway. Shen W. etc.\(^{19}\) established that oxidative stress-induced IncRNA-RP11-820 plays a key role in regulating the miR-3178/MYOD1/ECM axis in HTMCs. Moreover, our previous work\(^{20}\) had proved that knockdown of IncRNA NR_003923 in human Tenon's capsule fibroblast cells (HTFs) inhibited TGF-\(\beta\)-induced cell migration, proliferation, fibrosis and autophagy and overexpression of IL22RA1 enhanced HTFs migration and proliferation. Therefore, NR_003923 and IL22RA1 might contribute to glaucoma progression.
However, detailed analyses on expression profiling of lncRNAs in TM of POAG patients have not yet to be reported. Glaucoma has a complex pathogenesis and its symptoms are associated with the long-term intraocular pressure and damage, as well as apoptosis of retinal ganglion cells caused by various pathological factors. Among these multiple factors, IOP, the major risk one for the development and progression of glaucoma, is closely associated with TM tissue. The TM is a series of fenestrated beams and sheets of the extracellular matrix and is responsible for draining the aqueous humor from the eye via the anterior chamber. Therefore, TM tissue plays a crucial role in the development and progression of glaucoma. It would be more convincing to collect TM tissue rather than other ocular tissues for further microarray analyses. This study is the largest comparison of lncRNAs expression in the TM of normal controls and POAG patients reported to date. According to these results, lncRNAs ENST00000552367, ENST00000582505, ENST00000609130, NR_029395, NR_038379, and ENST00000586949 have highly expression in TM of POAG. These findings could point us to potential routes of therapy beyond that of intraocular pressure-lowering medications or surgery.

However, the sample size from our study was relatively small and these samples only came from the Chinese population. Also, the function of these lncRNA should be further verified through experiment in vivo and vitro.

**Conclusions**

We conclude that lncRNAs ENST00000552367, ENST00000582505, ENST00000609130, NR_029395, NR_038379, and ENST00000586949 may play essential roles in the development of POAG.

**Methods**

**Procurement of trabecular meshwork**

The study conforms to all tenets of the Declaration of Helsinki, and written informed consent was obtained from all subjects. This research was approved by the Ethics Committee of The Second Xiangya Hospital of Central South University (Changsha, China). All donated samples were obtained from The Second Xiangya Hospital.

Trabecular meshwork for test group were obtained from POAG patients who had uncontrolled IOP and accepted trabeculectomy surgery performed by one surgeon (XC. D). The inclusion criteria of POAG were the following: (1) age at POAG diagnosis older than 30 years, (2) glaucomatous optic nerve damage with associated visual field damage, and (3) exclude secondary glaucoma. All control TM tissue was obtained from donor eyes without glaucoma or glaucoma-associated condition.

**RNA isolation and qPCR**

TRIzol Reagent (Invitrogen Life Technologies, Carlsbad, CA) was used to extract total RNA from the TM samples. The total RNA quantity and quality were measured by NanoDrop ND-1000. RNA integrity was
assessed by standard denaturing agarose gel electrophoresis. Total RNA also purified with RNasey MinElute Cleanup Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. RNA was reverse transcribed into cDNA with the SuperScript™ III Reverse Transcriptase (Invitrogen, CA). Then, the cDNA was used for carrying out quantitative RT-PCR which conducted by SYBR green expression master mix (Applied Biosystems, Inc., Foster City, CA, USA). The forward and reverse primer sequences were listed in Table 2. The \( \Delta \Delta CT \) method \( (2^{-\Delta \Delta Ct}) \) was applied to calculate the relative differences between the control and POAG groups.
| Primer name          | Primer sequence                                                                 |
|---------------------|---------------------------------------------------------------------------------|
| 18S rRNA            | F:5’CAGCCACCCGAGATTGAGCA3’ R :5’ TAGTAGCGACGGGGCGGTG3’                           |
| ENST00000422366     | F:5’ CTCAGGACACCTCCCCTTG3’ R:5’ TGGGCATCCGTTTTGACT 3’                            |
| ENST00000430429     | F:5’ GCCACAATAGCAGAAGACCTA3’ R:5’ GTCTTGACAGATGGGAGACCA 3’                        |
| ENST00000514811     | F:5’ CTGAAGGAGGCCCCCTTG3’ R:5’ CGTCTGAACCTGAAAACGTTTGA 3’                         |
| ENST00000521373     | F:5’ TTGCGCTGTGGATGCTA3’ R:5’ CCTGACCTTGTGGACTGCT 3’                              |
| ENST00000523317     | F:5’ ACCTTACCTGTGCTGCGC3’ R:5’ GAGATCAAGAGCCGCACT 3’                            |
| ENST00000582505     | F:5’ ACTGAAGGGCCGACCCCCCTG3’ R:5’ CGAGGTGGCTGGGAAATGC3’                          |
| ENST00000583377     | F:5’ CAGTGGGCTCAATCAGCTCAGACT 3’ R:5’ AGATAACTGGGAAACCAGCACT 3’                  |
| ENST00000585387     | F:5’ CACCCAGACACAGAGGATTGC 3’ R:5’ TCTTCACAAGGGAGATCTG 3’                         |
| ENST00000609130     | F:5’ TTGAGCCTAGCGAGTTGCT 3’ R:5’ TTGGTGAGGCTAAGGATGGA3’                          |
| NR_003039           | F:5’ GCCTCCTTCCACAACCTCACTCA 3’ R:5’ AGGCTAGTCTCGGACT 3’                          |
| NR_024249           | F:5’ AGGCCAGAGACCATCGGTCTG 3’ R:5’ TGATCCCAAGCGGCAATA3’                          |
| NR_027425           | F:5’ GTGCCACAACCCGGAATCTTG 3’ R:5’ ATCAATTGGAGCRTGGA3’                           |
| NR_029395           | F:5’ AACAGAGCAACACAGAAATGCAT 3’ R:5’ CTGGGAACCTATGAACTTCT 3’                     |
| NR_038379           | F:5’ TACCTGTGCCAGGGCTTAT 3’ R:5’ TCTTCCCAACTAAACCCTGAG 3’                       |
| NR_046232           | F:5’ GAGCACTGAGACACCCCTTGACTT 3’ R:5’ AGCCACAGACCCCTTGACT 3’                     |

F, forward; R, reverse
| Primer name  | Primer sequence                                      |
|-------------|------------------------------------------------------|
| NR_110087   | F:5’ AGCAGTCCACCCCTGGCTG 3’<br>R:5’ CCAAATAGCTTGCACTGCTTG 3’ |
| uc002rhy.1  | F:5’ GAAAGTCGGATGCTGAAGATG 3’<br>R:5’ GCAGGTAGAGTAGTGTGAGGG 3’ |
| ENST00000586949 | F:5’ GAAGCAGGAAAAAGACTCCTCTTA 3’<br>R:5’ CAGTCTGTTGTACAAGGCAGAA 3’ |
| uc.3+       | F:5’ ATTTGCATAACCCAACCCC3’<br>R:5’ CGATGTCGTCTCTAATTACCC3’ |

F, forward; R, reverse

Microarray analysis

TM RNA samples from 4 control subjects and 4 POAG patients for microarray analyses were extracted and the RNA integrity was tested by standard denaturing agarose gel electrophoresis, as described above. RNA sample labeling and array hybridization were performed according to the Agilent One-Color Microarray-Based Gene Expression Analysis Protocol (Agilent, Santa Clara, CA). Briefly, mRNA was purified from total RNA after removal of rRNA (mRNA-ONLY™ Eukaryotic mRNA Isolation Kit, Epicentre). Then, each sample was amplified and transcribed into fluorescent cRNA along the entire length of the transcripts without 3’ bias utilizing a random priming method (Arraystar Flash RNA Labeling Kit, Arraystar). The labeled cRNAs were purified by RNeasy Mini Kit (Qiagen). The concentration and specific activity of the labeled cRNAs (pmol Cy3/µg cRNA) were measured by NanoDrop ND-1000. 1 µg of each labeled cRNA was fragmented by adding 5 µl 10 × Blocking Agent and 1 µl of 25 × Fragmentation Buffer, then heated the mixture at 60 °C for 30 min, finally 25 µl 2 × GE Hybridization buffer was added to dilute the labeled cRNA. 50 µl of hybridization solution was dispensed into the gasket slide and assembled to the IncRNA expression microarray slide. The slides were incubated for 17 hours at 65 °C in an Agilent Hybridization Oven. The hybridized arrays were washed, fixed and scanned with using the Agilent DNA Microarray Scanner (part number G2505C).

Data were extracted through the Agilent Feature Extraction software (Agilent, Santa Clara, CA). All original data have been uploaded to Gene Expression Omnibus public database (https://www.ncbi.nlm.nih.gov/geo; GSE138125).

GO and KEGG enrichment analysis

The Gene Ontology (GO) (http://www.geneontology.org) is a major bioinformatic tool to annotate genes and analyze biological process of these genes.24 Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.genome.jp/kegg) is a database resource for understanding high-level functions and biological systems from large-scale molecular datasets.25 P < 0.05 was considered statistically significant.
**Statistical analysis**

A train of data processing was performed through the R software package version 3.6.0\(^\text{26}\). Numeric variables were compared using t-test. Results were expressed as means ± standard deviation. All statistical analyses were performed with GraphPad Prism 7 (GraphPad Software, USA). The results were considered significant if P < 0.05.

**Declarations**

**Ethical Approval and consent to participate**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Second Xiangya Hospital research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

**Consent for publication**

All authors have given consent for publication.

**Availability of data and material**

All data are fully available without restriction.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work was supported in part by National Natural Science Foundation of China (Grant No. 8197033232, Grant No. 81670859 to X.D.), Science and Technology Foundation of Changsha Hunan, China (Grant No. kh1801229 to X.D.), Natural Science Foundation of Hunan Province, China (Grant No. 2019JJ40001 to X.D.), China Scholarship Council (No. 201906370215 to F.Z.), Postgraduate Independent Exploration and Innovation Project of Central South University (Grant No. 2018zzts258
to F.Z.).

Authors' contributions

FZ and XCD conceived and wrote the paper. FZ, YZ, MDC, ZP collected samples. FZ, XJ and DMZ recorded patient's information and made figures. KL and XCD reviewed and edited the manuscript.

Acknowledgements

Not applicable.

References

1. Resnikoff S, Keys TU. Future trends in global blindness. Indian J Ophthalmol. 2012;60:387–95. doi:10.4103/0301-4738.100532.
2. Quigley HA. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–7. doi:10.1136/bjo.2005.081224.
3. Jonas JB, et al. Glaucoma Lancet. 2017;390:2183–93. doi:10.1016/S0140-6736(17)31469-1.
4. Aung T, Khor CC. Glaucoma Genetics: Recent Advances and Future Directions. Asia Pac J Ophthalmol (Phila). 2016;5:256–9. doi:10.1097/APO.0000000000000229.
5. Fan BJ, et al. Genetic and environmental risk factors for primary open-angle glaucoma. Chin Med J (Engl). 2004;117:706–10.
6. Kountouras J, et al. Helicobacter pylori infection as an environmental familial clustering risk factor for primary open-angle glaucoma. Clin Exp Ophthalmol. 2008;36:296–7. doi:10.1111/j.1442-9071.2008.01729.x. author reply 297.
7. Elze T, Baniasadi N, Jin Q, Wang H, Wang M. Ametropia, retinal anatomy, and OCT abnormality patterns in glaucoma. 1. Impacts of refractive error and interartery angle. J Biomed Opt. 2017;22:1–11. doi:10.1117/1.JBO.22.12.121713.
8. Wostyn P, et al. Alzheimer's disease and glaucoma: can glymphatic system dysfunction underlie their comorbidity? Acta Ophthalmol. 2017;95:e244–5. doi:10.1111/aos.13068.
Kamat SS, Gregory MS, Pasquale LR. The Role of the Immune System in Glaucoma: Bridging the Divide Between Immune Mechanisms in Experimental Glaucoma and the Human Disease. Semin Ophthalmol. 2016;31:147–54. doi:10.3109/08820538.2015.1114858.

10.
Zou Y, et al. IncRNA expression signatures in periodontitis revealed by microarray: the potential role of IncRNAs in periodontitis pathogenesis. J Cell Biochem. 2015;116:640–7. doi:10.1002/jcb.25015.

11.
Zhao J, et al. Long non-coding RNA ANRIL down-regulates microRNA-7 to protect human trabecular meshwork cells in an experimental model for glaucoma. Eur Rev Med Pharmacol Sci. 2019;23:3173–82. doi:10.26355/eurrev_201904_17675.

12.
Xie L, et al. Potential Biomarkers for Primary Open-Angle Glaucoma Identified by Long Noncoding RNA Profiling in the Aqueous Humor. Am J Pathol. 2019;189:739–52. doi:10.1016/j.ajpath.2018.12.011.

13.
Burdon KP, et al. Glaucoma risk alleles at CDKN2B-AS1 are associated with lower intraocular pressure, normal-tension glaucoma, and advanced glaucoma. Ophthalmology. 2012;119:1539–45. doi:10.1016/j.ophtha.2012.02.004.

14.
Cabili MN, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011;25:1915–27. doi:10.1101/gad.17446611.

15.
Yan L, et al. Single-cell RNA-Seq profiling of human preimplantation embryos and embryonic stem cells. Nat Struct Mol Biol. 2013;20:1131–9. doi:10.1038/nsmb.2660.

16.
Ma L, et al. LncBook: a curated knowledgebase of human long non-coding RNAs. Nucleic Acids Res. 2019;47:D128–34. doi:10.1093/nar/gky960.

17.
Xu Y, Xing YQ. Long non-coding RNA GAS5 contributed to the development of glaucoma via regulating the TGF-beta signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22:896–902. doi:10.26355/eurrev_201802_14367.

18.
Li HB, et al. Long Non-Coding RNA-MALAT1 Mediates Retinal Ganglion Cell Apoptosis Through the PI3K/Akt Signaling Pathway in Rats with Glaucoma. Cell Physiol Biochem. 2017;43:2117–32. doi:10.1159/000484231.

19.
Shen W, Huang B, He Y, Shi L, Yang J. Long non-coding RNA RP11-820 promotes extracellular matrix production via regulating miR-3178/MYOD1 in human trabecular meshwork cells. FEBS J. 2019. doi:10.1111/febs.15058.

20.
Zhao Y, et al. LncRNA NR_003923 promotes cell proliferation, migration, fibrosis, and autophagy via the miR-760/miR-215-3p/IL22RA1 axis in human Tenon's capsule fibroblasts. Cell Death Dis. 2019;10:594. doi:10.1038/s41419-019-1829-1.

21. Tham YC, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–90. doi:10.1016/j.ophtha.2014.05.013.

22. Acott TS, et al. Intraocular pressure homeostasis: maintaining balance in a high-pressure environment. J Ocul Pharmacol Ther. 2014;30:94–101. doi:10.1089/jop.2013.0185.

23. Vranka JA, Kelley MJ, Acott TS, Keller KE. Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in glaucoma. Exp Eye Res. 2015;133:112–25. doi:10.1016/j.exer.2014.07.014.

24. Hassan H, Shanak S. GOTrapper: a tool to navigate through branches of gene ontology hierarchy. BMC Bioinformatics. 2019;20:20. doi:10.1186/s12859-018-2581-8.

25. Kanehisa M. The KEGG database. Novartis Found Symp. 2002;247:91–101. discussion 101–103, 119–128, 244 – 152.

26. Ihnatova I, Budinska E. ToPASeq: an R package for topology-based pathway analysis of microarray and RNA-Seq data. BMC Bioinformatics. 2015;16:350. doi:10.1186/s12859-015-0763-1.

**Figures**

**Figure 1**

Microarray expression profiling of long noncoding RNAs (lncRNAs) and mRNAs in the trabecular meshwork (TM). (A) (B): Heat maps of lncRNAs (A) and mRNAs (B) microarray expression profiling in TM of normal controls and primary open-angle glaucoma (POAG) patients. (C) (D): Scatter plots of lncRNAs (C) and mRNAs (D) expression profile. (E) (F): Volcano plots of differentially expressed lncRNAs (E) and mRNAs (F) in TM between control group and POAG group. The vertical green lines and horizontal green line indicate cutoff lines for fold change and P values, respectively (fold change≤0.5 or≥2, and P≤0.05).

**Figure 2**

Gene Ontology (GO) enrichment analyses. (A) up-regulated genes, (B) down-regulated genes.
Figure 3

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. (A) KEGG pathway enrichment analyses showing 10 pathways enriched among up-regulated genes. (B) KEGG pathway enrichment analyses showing 10 pathways enriched among down-regulated genes. DE, differentially expressed.

Figure 4

Real-time quantitative PCR validation of 20 lncRNAs in TM samples from Control group and POAG group. Data are expressed as means ± SD.

Figure 5

Real-time quantitative PCR showing expression of ENST00000422366 (A), ENST00000552367 (B), ENST00000582505 (C), ENST00000609130 (D), NR_029395 (E), NR_038379 (F), NR_110087 (G), and ENST00000586949 (H) in TM of control group and POAG group. Data are expressed as means ± SD.